Taysha Gene Therapies to Participate in Upcoming June Investor Healthcare Conferences
May 26 2021 - 07:00AM
Business Wire
Jefferies Virtual Healthcare Conference on June
2, 2021 at 10:30 am ET
Goldman Sachs 42nd Annual Global Healthcare
Conference on June 10, 2021 at 5:30 pm ET
JMP Securities Life Science Conference on June
16, 2021 at 12:30 pm ET
Taysha Gene Therapies, Inc. (Nasdaq: TSHA), a patient-centric,
pivitol-stage gene therapy company focused on developing and
commercializing AAV-based gene therapies for the treatment of
monogenic diseases of the central nervous system (CNS) in both rare
and large patient populations, today announced its participation in
a virtual fireside chat for the Jefferies Virtual Healthcare
Conference, Goldman Sachs 42nd Annual Global Healthcare Conference,
and the JMP Securities Life Science Conference.
Conferences Details:
Event:
Jefferies Virtual Healthcare
Conference
Date:
Wednesday, June 2, 2021
Time:
10:30 am ET
Format:
Fireside chat
Participants:
RA Session II, President, Founder and
CEO
Dr. Suyash Prasad, Chief Medical Officer
and Head of R&D
Kamran Alam, Chief Financial Officer
Event:
Goldman Sachs 42nd Annual Global
Healthcare Conference
Date:
Thursday, June 10, 2021
Time:
5:30 pm ET
Format:
Fireside chat
Participants:
RA Session II, President, Founder and
CEO
Dr. Suyash Prasad, Chief Medical Officer
and Head of R&D
Kamran Alam, Chief Financial Officer
Event:
JMP Securities Life Science Conference
Date:
Wednesday, June 16, 2021
Time:
12:30 pm ET
Format:
Fireside chat
Participants:
RA Session II, President, Founder and
CEO
Dr. Suyash Prasad, Chief Medical Officer
and Head of R&D
Kamran Alam, Chief Financial Officer
Webcasts for these conferences will be available in the “Events
& Media” section of the Taysha corporate website at
https://ir.tayshagtx.com/news-events/events-presentations. Archived
versions of the webcasts will be available on the website for 60
days.
About Taysha Gene Therapies
Taysha Gene Therapies (Nasdaq: TSHA) is on a mission to
eradicate monogenic CNS disease. With a singular focus on
developing curative medicines, we aim to rapidly translate our
treatments from bench to bedside. We have combined our team’s
proven experience in gene therapy drug development and
commercialization with the world-class UT Southwestern Gene Therapy
Program to build an extensive, AAV gene therapy pipeline focused on
both rare and large-market indications. Together, we leverage our
fully integrated platform—an engine for potential new cures—with a
goal of dramatically improving patients’ lives. More information is
available at www.tayshagtx.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210526005417/en/
Company Contact: Kimberly Lee, D.O. SVP, Corporate
Communications and Investor Relations Taysha Gene Therapies
klee@tayshagtx.com
Media Contact: Carolyn Hawley Canale Communications
carolyn.hawley@canalecomm.com
Taysha Gene Therapies (NASDAQ:TSHA)
Historical Stock Chart
From Feb 2024 to Mar 2024
Taysha Gene Therapies (NASDAQ:TSHA)
Historical Stock Chart
From Mar 2023 to Mar 2024